Winner 2015

Entlastung für Herz und Lunge

A relief for heart and lung - from nitroglycerin to innovative therapies

Prof. Dr. med. Ardeschir Ghofrani* (Spokesperson)
Dr. med. Reiner Frey
Prof. Dr. rer. nat. habil. Johannes-Peter Stasch
Bayer Pharma AG, Wuppertal
*Justus-Liebig-Universität Gießen

(f.l.t.r.) Prof. Dr. med. Ardeschir Ghofrani, Prof. Dr. rer. nat. habil. Johannes-Peter Stasch, Dr. med. Reiner Frey

People who suffer from pulmonary hypertension are forced to accept that their quality of life is severely limited. Many patients die within a few years of diagnosis. Is there any way to stop this from happening?

Prof. Dr. Ardeschir Ghofrani, Dr. Reiner Frey and Prof. Dr. Johannes-Peter Stasch have developed an innovative drug that is effective in treating two forms of the serious and progressive disease. In the course of their work, the researchers discovered a mechanism of action that directly affects the molecular processes in the cardio-pulmonary system - and in the future could also be used to treat a number of other diseases. Johannes-Peter Stasch is an honorary professor for pharmaceutical research at the University of Halle-Wittenberg and was the senior fellow in cardiovascular research at Bayer Pharma AG. Reiner Frey also worked at Bayer as a senior fellow in clinical pharmacology. Ardeschir Ghofrani is head of the Pulmonary Hypertension Clinic at University Clinic Giessen und Marburg and is medical director of the Kerckhoff Clinic in Bad Nauheim.

The use of nitroglycerin in the treatment of cardiovascular diseases began 130 years ago. Initially used as an explosive, it is administered to treat angina pectoris. In the body, it releases nitric oxide (NO) that dilates blood vessels and lowers blood pressure, but it also degrades rapidly.

The body also produces NO. Patients with pulmonary hypertension do not produce enough NO and the pressure in the pulmonary arteries rises. Affected persons suffer from shortness of breath which makes everyday activities such as climbing stairs or walking longer distances difficult. Added to this are fatigue and circulatory problems that may result in fainting spells. Untreated, patients usually die of heart failure within a few years.

To date, treatments to relieve pulmonary hypertension are available only for two types of the disease. Restoration of health can only be achieved for one form by means of an operation and the other form cannot be treated - a drug therapy has still not been found for the first type. Until now.

NO acts together with an enzyme that imparts its vasodilatory effect to the cells: "soluble guanylate cyclase" (sGC). Bayer researchers discovered a way to stimulate sGC independent of NO in 1994. Together with scientists from Giessen, they proved that this was an effective and promising way to treat pulmonary hypertension. Riociguat, the first active agent suitable to treat the disease, was synthesized for the first time in 2000. Thanks to its dual mechanism of action, Riociguat increases the effects of NO or replaces it to stimulate sGC to lower blood pressure in the lungs.

On the basis of this discovery, BAYER has developed the drug ADEMPAS® that is now approved in over 50 countries. It is effective in treating the symptoms of the disease and slows its progression. In the USA, it has been approved for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) - a form of the disease that has never before able to be treated by medication - if an operation is not possible or has been unsuccessful. The drug has also proven effective for certain types of pulmonary arterial hypertension (PAH). The drug was approved in the European Union in March 2014. Ongoing long-term studies have since documented that it is effective and safe over a period of up to two years. Other active agents from this class of substances are meanwhile being clinically tested for other diseases, e.g. in the treatment of chronic heart failure (cardiac insufficiency).

In addition to the great medical benefits, the drug also has vast commercial potential. Forecasts suggest annual turnover in excess of Euro 500m in the coming years. The development of the new drug for the treatment of pulmonary hypertension is exemplary of successful pharmaceutical innovation in Germany. The pharmacological principle was discovered in Germany. The active substance was developed and tested in Germany. The drug is produced in Germany. This has resulted in and will create numerous new jobs.

The right to nominate outstanding achievements for the Deutscher Zukunftspreis is incumbent upon leading German institutions in science and industry as well as foundations.

The project "A relief for heart and lung - from nitroglycerin to innovative therapies" was nominated by acatech – National Academy of Science and Engineering e.V..

more details

Resumes

Prof. Dr. med. Ardeschir Ghofrani

Prof. Dr. med. Ardeschir Ghofrani

07.06.1967
Born in Clausthal-Zellerfeld
1986
Abitur – diploma from German secondary school qualifying for university admission or matriculation
1986
Study of chemistry, RWTH Aachen
1987 – 1994
Medical school Justus-Liebig-University Giessen
1994 – 2003
Resident, Medical Clinic II, University Hospital Giessen
2003
Senior house officer, Medical Clinic II, University Hospital, Head of Pulmonary Hypertension Outpatient Clinic
2004
Specialist Internal Medicine (medical licence)
2005
Habilitation in Internal Medicine, topic „Inhaled Prostanoids and Phosphodiesterase-5-Inhibitors for the Treatment of Pulmonary Hypertension“
2006
Associate Professor for Internal Medicine, JLU Giessen
since 2007
„Area Leader“ at the Excellence Cluster Cardiopulmonary System (ECCPS)
since 2007
Member of the Steering Committee of the ECCPS
since 2009
Full Professor „Chair for Pulmonary Vascular Research“ JLU Gießen, Germany
since 2009
Head of Department Pneumology, Kerckhoff-Clinic Bad Nauheim, Germany
since 2009
Medical Executive Director, Kerckhoff-Clinic Bad Nauheim, Germany
since 2013
Professor for Pulmonary Vascular Medicine, Department of Medicine, Imperial College London, UK (part time)

Honors:

2002
“Travel Award” of the American Thoracic Society; Pulmonary Circulation Assembly
2002
Francois Brenot Award of the European Respiratory Society “For promising young investigator in pulmonary vascular sciences”
2004
Award of the “René-Baumgart-Foundation”
2004
Paul-Martini-Prize

Dr. med. Reiner Frey

Dr. med. Reiner Frey

06.10.1949
Born in Nagold
1968
Abitur, High School, Nagold
1971 – 1977
Medical Studies, Eberhard Karls University Tübingen
1977 – 1978
Medicinal Assistant at the department „anesthesia, surgery and internal medicine”
1978
License to practice medicine („Approbation“)
1978
Ph. D., at the chair and department for pediatric cardiology at the Eberhard Karls University Tübingen,
Topic: „Echocardiographic findings in the infantile Idiopathic Hypertrophic Subaortic Stenosis“
1979 – 1986
Medical specialists training in pediatrics and pediatric cardiology at the University children’s hospital in Tübingen
1986
Medical specialist approval in pediatrics and pediatric cardiology
1987
Qualification in emergency medical services
1988
Additional qualification in sports medicine
1986 – 1988
Resident physician at the Department for Internal Medicine at the county hospital in Nagold
1989 - 2015
International Clinical Project Lead, Department of Clinical Pharmacology, Bayer AG, Wuppertal
since 1998
Clinical development of sGC-stimulators
2004
Start of the clinical development of Riociguat
2010
Chief Scientist, Bayer HealthCare
since 2015
Senior Consultant

Prof. Dr. rer. nat. habil. Johannes-Peter Stasch

Prof. Dr. rer. nat. habil. Johannes-Peter Stasch

18.08.1954
Born in Hessisch-Oldendorf
1965 – 1973
Schiller High School, Hameln, “Abitur” examination
1973 – 1978
Studies Leibniz University Hannover and Julius-Maximilians-University Würzburg Degree dissertation, Physical Chemistry Department, Julius-Maximilians- University, Würzburg
1978 – 1980
Alternative civilian service Neurochemistry Department, Würzburg University Hospital
1980 – 1983
Doctorate Dr. rer. nat., Neuropharmacology Department, Würzburg University Hospital, and Inorganic Chemistry Department, Bielefeld University,
Topic: Sila-piperidines and silylated piperidines with potential anti-Parkinson activity – syntheses, receptor binding studies and influences on the chemical signal transmission in the central nervous system”.
1980 – 1983
Pharmacy studies Julius-Maximilians- University, Würzburg
1983 – 1984
Internship Raths-Apotheke pharmacy, Hameln, and Pharma Hameln GmbH
1984
License to practice pharmacy
1984
Laboratory head at Bayer AG’s Institute for Cardiovascular Research in Wuppertal,
Research Scientist
1985
Senior Research Scientist Bayer AG Wuppertal
1990
Principal Research Scientist
1991
Qualification as a specialist in drug product information
1991
Authorization to train students in drug product information
1995
Research Fellow
2003
Qualification to teach pharmacology, Martin-Luther-University, Halle-Wittenberg University, associate professor
2004
Senior Research Fellow, Bayer AG, Wuppertal
2008
Chief Scientist, Bayer HealthCare
2010
Honorary professor of Industrial Drug Discovery and Development
2015
Senior Consultant Bayer AG Wuppertal

Honors:

2008
European Federation of Pharmaceutical Industries and Associations (EFPIA)
“Achievements in fundamental research in cardiology”
2008
Otto Bayer Medal
2013
Elected a member of Deutsche Akademie der Naturforscher Leopoldina - Nationale Akademie der Wissenschaften

Contact

Spokesperson

Prof. Dr. Ardeschir Ghofrani
Universitätsklinikum Gießen
Klinikstraße 36
35392 Gießen
Phone: + 49 (0) 641 / 99 42 422
E-Mail: Ardeschir.Ghofrani@innere.med.uni-giessen.de
www.uni-giessen.de

Press

Dr. Katharina Jansen
Brand, Communication & Government Relation, Science & Research
Bayer AG
Phone: +49 (0) 214 / 30 33 243
E-Mail: katharina.jansen@bayer.com
www.bayer.com

A description provided by the institutes and companies regarding their nominated projects

Pulmonary Hypertension and the Innovative Treatment Option for this breath-taking disease
Riociguat is the first in an innovative class of medicines approved for the treatment of two life-threatening forms of pulmonary hypertension (PH) – namely, inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgical treatment, and specific forms of pulmonary arterial hypertension (PAH). Patients with PH have a significantly limited quality of life and experience a decrease in physical performance, shortness of breath, and fainting for cardiovascular reasons, which severely reduce their ability to perform even everyday activities such as climbing stairs or household activities. If patients remain untreated, pulmonary hypertension will result in death due to heart failure within very few years.

A drug to restore the body’s natural mechanism
Nitroglycerine began life as an explosive substance! However, for more than 130 years it has also been used in medicine as a remedy for angina pectoris because of its vasodilatory effects. In the human body, nitroglycerin acts by releasing nitric oxide (NO). Functions of NO include, among others, the regulation of vessel diameter and blood pressure. This discovery has been awarded with the Nobel Prize for Medicine in 1998. However, nitroglycerine degrades rapidly and therefore is not suitable as a long-term medication.

NO is also synthesized by the body itself. Patients with PH have an impaired capacity to make their own NO, leading to the increase of blood pressure in the arteries of their lungs. However, NO has a partner, an enzyme called soluble guanylate cyclase (sGC) which mediates the vasodilatory effect of NO.

At Bayer, scientists began intense search for substances which enhance NO synthesis in 1994. Unexpectedly, they discovered direct stimulators of sGC, and, thus, a new way to dilate blood vessels and to relieve the heart. In 1997, after having synthesized and tested 4000 substances, the first potential drug candidates were identified. The breakthrough was achieved in the year 2000 when the active substance riociguat was synthesized. Riociguat stimulates sGC directly and in addition to that brings the enzyme into a status that makes it more sensitive to the body’s own NO.

At the same time, scientists at the lung research center of the Justus Liebig University at Giessen showed that medications that increase the effects of NO or even replace NO altogether constitute a promising new therapeutic option for pulmonary hypertension.

Meanwhile, there is an emerging body of evidence suggesting that sGC stimulators might have therapeutic benefits in many other cardiovascular diseases that are associated with defects of the NO-sGC signaling pathway. In a worldwide strategic collaboration, Bayer and its partner MSD (known as Merck in the U.S. and Canada) are currently working to investigating this potential in a comprehensive study program.

Pulmonary Hypertension – A life-threatening disease
When oxygen is scarce (e.g. at high altitudes), the walls of the lung vessels react by narrowing. This is a natural adaptation mechanism in all mammals. However, the human body is not adapted to a continuous increased pressure in the pulmonary circulation system. There are five different types of PH with different causes but similar impact on most patients.

Chronic thromboembolic pulmonary hypertension or CTEPH is a type of PH caused by recurrent blood clots washed into the lungs with the blood stream but originating in distant veins (so-called emboli). Usually such clots are degraded by the body, but in CTEPH patients the clots form scars and lead to permanent occlusion of some of the pulmonary arteries. Blood from the right ventricle, pumped into the lungs to be loaded with oxygen, must now be pumped through significantly fewer vessels. This leads to an increased pressure and ultimately may result in heart failure and death. For many patients, a surgical procedure to re-open the blocked branches of the pulmonary arteries is a potential cure. However, 20-40% of CTEPH patients are not operable and in up to 35% of patients, the disease persists or reoccurs after surgery. These patients need an effective pharmacological treatment. With Riociguat, there is now an approved medication available – for the first time ever.

Pulmonary arterial hypertension or PAH is also characterized by an increased blood pressure in the pulmonary circulation system, but in this case, apart from a narrowing of the arteries, uncontrolled cell growth is the cause of the disease. PAH can have a genetic cause, but apart from that, this equally deadly form of pulmonary hypertension can also be caused by infection, certain toxins and some drugs. In spite of several approved drugs available for patients with PAH, the prognosis for these patients has remained poor, resulting in the need for new treatment options.

Pharmaceutical Innovation, from bench to bedside, in Germany
Riociguat is an outstanding example of how German industry and academia worked closely together to bring an important and innovative treatment to severely ill patients all over the world. The distinct mode of action of sGC stimulation and its medical significance were discovered by Bayer scientists in Wuppertal, Germany. In the research and development of Riociguat for the treatment of pulmonary hypertension, Bayer collaborated with leading experts at the “Excellence Cluster Cardio-Pulmonary System” (ECCPS) at the Justus Liebig University in Giessen. This collaboration was the key success factor for the project.

Starting from this cooperation, clinical trials were performed at expert centers throughout Germany. Their results confirmed the early research promise, with clear signs of efficacy in PAH and CTEPH patients. With Prof Ghofrani at Giessen as the lead investigator, larger studies were then initiated worldwide. These confirmed the efficacy and safety of riociguat and in March 2014 led to its approval by the European Commission under the name Adempas®. Adempas is now approved in over 50 countries worldwide, including the U.S. and Japan.

Adempas is manufactured and packaged in Germany and shipped throughout the world. One year after launch, based on the feedback received from doctors and their patients, it can be said that Adempas has helped many patients with pulmonary hypertension to be able to live a more active life again.

The mutual exchange and use of know-how and expertise are at the forefront of the collaboration between Bayer and the lung research center in Giessen, and this continues with the search for other rare diseases that may be treated with this distinct drug.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed around 119,000 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. These figures include those for the high-tech polymers business, which is to be floated on the stock market as Covestro.

About Justus-Liebig-Universität Gießen
Founded in 1607, Justus Liebig University Giessen (JLU) is a research university with a long-standing tradition which attracts some 28,000 students. Apart from the wide range of subjects on offer ‒ extending from classical natural sciences, law and economics, social and educational sciences to linguistics and cultural studies it offers a selection of life science subjects that is unique not only in Hesse: human and veterinary medicine, agricultural, environmental and nutritional sciences and food chemistry. The leading personae who carried out research and taught at JLU include a number of Nobel prizewinners, such as Wilhelm Conrad Röntgen (Nobel Prize for Physics in 1901) and Wangari Maathai (Nobel Peace Prize in 2004). Since 2006 JLU has been receiving financial support under both the first and the second Excellence Initiative promotional schemes (Excellence Cluster Cardio-Pulmonary System – ECCPS; International Graduate Centre for the Study of Culture – GCSC).

The right to nominate outstanding achievements for the Deutscher Zukunftspreis is incumbent upon leading German institutions in science and industry as well as foundations.

The project "A relief for heart and lung - from nitroglycerin to innovative therapies" was nominated by acatech – National Academy of Science and Engineering e.V..

Nominee 2015 · TEAM 1